Cancer News

FDA Approves Adcetris® in Combination with Chemotherapy for Previously Untreated Stage III or IV Classical Hodgkin Lymphoma (03/22/2018)

CancerConnect News: The U.S. Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) in combination with chemotherapy in adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma. The approval is based on the successful outcome of the ECHELON-1 clinical trial that compared Adcetris plus AVD (Adriamycin, vinblastine and dacarbazine) to ABVD …

Continue reading "FDA Approves Adcetris® in Combination with Chemotherapy for Previously Untreated Stage III or IV Classical Hodgkin Lymphoma"

Addition of the Precision Cancer Medicine Adcetris Reduces the Risk of Treatment Failure in Advanced Hodgkin Lymphoma (03/01/2018)

CancerConnect News: Patients with advanced Hodgkin lymphoma (HL) who were treated with a multi-drug regimen that included the precision cancer medicine Adcetris (brentuximab vedotin) had a 23-percent reduction in the risk of disease progression, death, or the need for additional therapy, compared with patients who received the standard treatment for advanced HL.1 Hodgkin’s lymphoma is …

Continue reading "Addition of the Precision Cancer Medicine Adcetris Reduces the Risk of Treatment Failure in Advanced Hodgkin Lymphoma"

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions (12/01/2016)

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring transfusions. These results were recently published in the New England Journal of Medicine. Many patients with cancer require red blood cell transfusions, either in response to the disease itself, or … Continue reading "Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions"

CAR Therapy Effective in Advanced Lymphoma (06/20/2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types of lymphomas. This type of treatment is continuing to produce impressive results, and is demonstrating effectiveness in several different types … Continue reading "CAR Therapy Effective in Advanced Lymphoma"

Defitelio® Approved for Life-Threatening Complication of Stem Cell Transplant (03/30/2016)

The United States Food and Drug Administration (FDA) has approved Defitelio® (defibrotide sodium) for the treatment of hepatic veno-occlusive disease (VOD) following a stem cell transplant. Defitelio is the first approved treatment for severe hepatic VOD. Hepatic VOD is a rare, but life-threatening complication that can occur following chemotherapy and a stem cell transplant (SCT) … Continue reading "Defitelio® Approved for Life-Threatening Complication of Stem Cell Transplant"